Live
- South Korean FM Cho, Blinken hold talks on margins of APEC summit in Peru
- India’s insurance sector growth surpasses China, Thailand: McKinsey
- CLOSE-IN: Indian cricketers from Paupers to Princelings
- Delhi-NCR's air quality remains hazardous for residents
- South Korea, US, Japan to announce establishment of trilateral secretariat this week
- North Korean leader Kim orders mass production of suicide attack drones: KCNA
- Calcutta HC to hear next week plea for CBI probe into death of Jhargram Hospital doc
- Nigeria reports 15,000 AIDS-related deaths annually: Official
- The quicker Mohammed Shami gets fit and is on a flight, it's better for India, says Shastri
- BGT 2024-25: KL Rahul, Sarfaraz Khan suffer elbow in injuries; Virat Kohli taken for scans as India finish first practice session
Glenmark Pharma receives ANDA tentative approval for Dabigatran Etexilate Capsules
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd (Glenmark) today announced that it has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg, the generic version of Pradaxa®1 Capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Ltd (Glenmark) today announced that it has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg, the generic version of Pradaxa®1 Capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
In a regulatory filing, Glenmark Pharmaceuticals said, "Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg."
According to IQVIATM sales data for the 12 months ending October 2020, the Pradaxa® Capsules, 75 mg, 110 mg, and 150 mg market achieved annual sales of approximately $550.9 million.
Glenmark's current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals Ltd. is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019).
